Broker’s Call: Fortis Healthcare (Buy)

Why It Matters

The turnaround positions Fortis as a high‑growth, undervalued player in India’s expanding private‑hospital market, offering investors a compelling upside at attractive multiples.

Key Takeaways

• IHH Healthcare took control in FY19, driving professional management.
• EBITDA grew 33% CAGR, reaching ~₹2,050 crore ($247 M) FY26E.
• Bed capacity expansion fuels faster EBITDA break‑even.
• Target price ₹1,100 ($13) implies ~18% upside from current price.
• Valuation uses 30× EV/EBITDA for hospitals, 23× for diagnostics.

Pulse Analysis

Fortis Healthcare’s resurgence illustrates how strategic ownership changes can revitalize a stressed asset. After IHH Healthcare acquired a controlling stake in FY‑19, the company embarked on a rigorous balance‑sheet cleanup, shedding non‑core businesses and tightening governance. These moves have restored stakeholder confidence and laid the groundwork for operational discipline, a critical factor in a sector where capital intensity and regulatory scrutiny are high. The hospital chain’s renewed focus on core services aligns with broader trends in India’s private‑healthcare expansion, driven by rising middle‑class demand and government support for medical infrastructure.

Financially, Fortis has posted a striking turnaround. EBITDA has surged at a 33% compound annual growth rate, projected to reach roughly ₹2,050 crore ($247 M) by FY 26E, while revenue is expected to climb to about ₹9,000 crore ($1.08 B). The firm’s bed capacity has expanded significantly, improving economies of scale and accelerating the path to EBITDA break‑even for new facilities. Compared with peers such as Max Healthcare and Apollo Hospitals, Fortis now commands valuation multiples—30× forward EV/EBITDA for hospitals and 23× for diagnostics—that are in line with industry standards, suggesting the market recognizes the sustainability of its earnings momentum.

For investors, the broker’s Buy rating hinges on both the upside potential and the relative discount to peers. At a target price of ₹1,100 ($13), the stock offers roughly an 18% premium over the current level, reflecting confidence in continued earnings growth and disciplined capital allocation. Risks remain, including execution of further bed additions and macro‑economic pressures on discretionary health spending. Nonetheless, Fortis’s transformation story, combined with a favorable valuation and a robust Indian healthcare outlook, makes it a noteworthy candidate for portfolios seeking exposure to high‑growth emerging‑market health services.